MX2018000189A - Metodo para el diagnostico de la enfermedad de farber. - Google Patents
Metodo para el diagnostico de la enfermedad de farber.Info
- Publication number
- MX2018000189A MX2018000189A MX2018000189A MX2018000189A MX2018000189A MX 2018000189 A MX2018000189 A MX 2018000189A MX 2018000189 A MX2018000189 A MX 2018000189A MX 2018000189 A MX2018000189 A MX 2018000189A MX 2018000189 A MX2018000189 A MX 2018000189A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- farber
- diagnosis
- subject
- ceramide
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01023—Ceramidase (3.5.1.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se refiere a un método para diagnosticar la enfermedad de Farber en un sujeto, en donde el método comprende la detección de ceramida de C26 en una muestra del sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15002041.0A EP3115786A1 (en) | 2015-07-08 | 2015-07-08 | Method for the diagnosis of farber's disease |
PCT/EP2016/001182 WO2017005374A1 (en) | 2015-07-08 | 2016-07-08 | Method for the diagnosis of farber's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018000189A true MX2018000189A (es) | 2018-08-01 |
Family
ID=53673711
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018000189A MX2018000189A (es) | 2015-07-08 | 2016-07-08 | Metodo para el diagnostico de la enfermedad de farber. |
Country Status (8)
Country | Link |
---|---|
US (1) | US11204357B2 (es) |
EP (2) | EP3115786A1 (es) |
CN (1) | CN109348728A (es) |
AU (1) | AU2016290904A1 (es) |
BR (1) | BR112017027304A2 (es) |
CA (1) | CA2991345A1 (es) |
MX (1) | MX2018000189A (es) |
WO (1) | WO2017005374A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2020008377A (es) * | 2018-03-27 | 2020-09-25 | Enzyvant Therapeutics Gmbh | Marcadores de la enfermedad de farber y usos de estos. |
GB201916046D0 (en) * | 2019-11-04 | 2019-12-18 | Amazentis Sa | Diagnostic method |
WO2023232942A1 (en) * | 2022-06-01 | 2023-12-07 | Universiteit Antwerpen | Method for detecting lysosomal storage disease biomarkers and kits for performing the method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100233680A1 (en) * | 2005-11-12 | 2010-09-16 | Siemens Healthcare Diagnostics Inc. | Gene Expression Profiles and Methods of Use |
-
2015
- 2015-07-08 EP EP15002041.0A patent/EP3115786A1/en not_active Ceased
-
2016
- 2016-07-08 AU AU2016290904A patent/AU2016290904A1/en not_active Abandoned
- 2016-07-08 CN CN201680039756.4A patent/CN109348728A/zh active Pending
- 2016-07-08 MX MX2018000189A patent/MX2018000189A/es unknown
- 2016-07-08 EP EP16744301.9A patent/EP3320344A1/en not_active Ceased
- 2016-07-08 CA CA2991345A patent/CA2991345A1/en not_active Abandoned
- 2016-07-08 US US15/742,317 patent/US11204357B2/en active Active
- 2016-07-08 BR BR112017027304A patent/BR112017027304A2/pt not_active IP Right Cessation
- 2016-07-08 WO PCT/EP2016/001182 patent/WO2017005374A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BR112017027304A2 (pt) | 2018-09-04 |
CN109348728A (zh) | 2019-02-15 |
AU2016290904A1 (en) | 2018-01-04 |
CA2991345A1 (en) | 2017-01-12 |
US11204357B2 (en) | 2021-12-21 |
US20180203024A1 (en) | 2018-07-19 |
WO2017005374A1 (en) | 2017-01-12 |
EP3320344A1 (en) | 2018-05-16 |
EP3115786A1 (en) | 2017-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017006785A (es) | Metodos y composiciones para radioetiquetado con 18f de productos biologicos. | |
MY194686A (en) | Detection of chromosome interactions | |
MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
WO2015061634A3 (en) | Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders | |
IL246917B (en) | Biomarker and early diagnosis methods for Alzheimer's disease | |
WO2012173976A3 (en) | Methods and apparatus for assessing activity of an organ and uses thereof | |
EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
EP3587597C0 (en) | METHOD FOR DIAGNOSING PARKINSON'S DISEASE BY BACTERIAL METAGENOME ANALYSIS | |
MX2018014028A (es) | Inmunomoduladores de produccion de imagenes de tomografia por emision de positrones (pet). | |
MX2018012856A (es) | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. | |
WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
MA39804A (fr) | Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin | |
EP2723866A4 (en) | METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES | |
EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
MX358474B (es) | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. | |
MX2016004167A (es) | Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal. | |
MX2023005452A (es) | Deteccion de beta amiloide por espectrometria de masas. | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
EP3757224A3 (en) | Method of assessing risk of pml | |
EP3285071A4 (en) | Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method | |
EP3567118A4 (en) | METHOD OF DIAGNOSING HEART DISEASES BY BACTERIAL METAGENOMANALYSIS | |
MX359328B (es) | Metodo para el diagnostico de enfermedad de niemann-pick. | |
WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same | |
NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
WO2015168602A3 (en) | Methods and compositions for the diagnosis and treatment of kawasaki disease |